Allarity CEO to present at Biomarkers & Precision Medicine 2025 in London on Oct 1

Allarity Therapeutics, Inc.

CEO Thomas Jensen invited to present at Oxford Global conference on October 1, 2025.
Presentation title: 'A Gene Expression Based Biomarker For Predicting Response To Treatment With Stenoparib'.
Jensen will also be interviewed by Oxford Global's editorial team for their online portal.
Jensen available for one-on-one meetings during the conference to discuss business development.
Allarity is a Phase 2 clinical-stage company developing dual PARP/WNT inhibitor stenoparib.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.